Precigen Inc (I5X.BE)
Berlin - Berlin Delayed price. Currency in EUR
Add to watchlist
As of 08:30PM CEST. Market open.
| Previous close | 1.5490 |
| Open | 1.5630 |
| Bid | 1.4090 x N/A |
| Ask | 1.5280 x N/A |
| Day's range | 1.4680 - 1.5700 |
| 52-week range | 0.8200 - 1.7000 |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 07 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Simply Wall St.Is Precigen (NASDAQ:PGEN) In A Good Position To Invest In Growth?
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
- Simply Wall St.
Precigen (NASDAQ:PGEN) shareholders are up 15% this past week, but still in the red over the last three years
Precigen, Inc. ( NASDAQ:PGEN ) shareholders should be happy to see the share price up 15% in the last week. But only...
PR NewswirePrecigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response
Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today released positive Phase 1/2 pivotal study results for the investigational PRGN-2012 off-the-shelf (OTS) AdenoVerse® gene therapy in patients with recurrent respiratory papillomatosis (RRP). Results were presented in a late-breaking oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting by Scott
© 2024 Yahoo. All rights reserved.